Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the company does not produce a plague vaccine, unlike Moderna and Pfizer, which saw modest gains. The market is distinguishing between direct vaccine sellers like Moderna and companies like Novavax that rely on royalties. Investors will watch for further official updates that could impact vaccine stock movements.
Novavax trades at USD 11.42 on Pluang, down 9.08% as of Oct 06, 2026 21:14 WIB, reflecting a sharper decline than the article's 2%. Moderna is also down 6.82% at USD 189.35, while Pfizer shows a slight drop of 0.13% at USD 27.38. Despite the news, Pluang order activity favors buying Novavax and Pfizer, with 90% and 91% buy orders respectively, compared to a more balanced 52% buy for Moderna.
